Prosecution Insights
Last updated: April 19, 2026

Innate Pharma

6 pending office actions

Portfolio Summary

6
Total Pending OAs
2
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18432126 VARIABLE REGIONS FOR NKP46 BINDING PROTEINS ROONEY, NORA MAUREEN 1641 Final Rejection Feb 05, 2024
18490804 MULTISPECIFIC NKp46 BINDING PROTEINS HUYNH, PHUONG N 1641 Non-Final OA Oct 20, 2023
18285668 IMMUNOHISTOCHEMISTRY METHODS AND KIR3DL2-SPECIFIC REAGENTS CHANDRA, GYAN 1674 Non-Final OA Oct 05, 2023
18283385 MULTISPECIFIC PROTEINS COMPRISING AN NKP46-BINDING SITE, A CANCER ANTGIENGE BINDING SITE FUSED TO A CYTOKINE FOR NK CELL ENGAGING JOHNSON, TIRONE DEREK 1675 Non-Final OA Sep 21, 2023
18331966 NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES PUTTLITZ, KARL J 1646 Final Rejection Jun 09, 2023
18020436 CELL SURFACE MICA AND MICB DETECTION USING ANTIBODIES MOSELEY II, NELSON B 1642 Non-Final OA Feb 09, 2023

Managing Innate Pharma's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month